The FDA approved once-weekly semaglutide for weight loss injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition Weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014. Semaglutide for weight loss is indicated for chronic weight management in adults with a BMI of 27 kg/m² or greater who have at least one weight-related comorbidity, such as type 2…

The FDA approved Novo Nordisk's injectable semaglutide weight management (Wegovy) for adults with obesity or overweight. The GLP-1 receptor was approved for chronic weight management in adults with obesity (BMI of 30 or greater) or for adults with overweight (BMI 27 or greater) with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol, used in conjunction with a reduced calorie diet and an exercise regimen. The once-weekly, injectable medication is approved at a dose of 2.4 mg for…

For those looking to get the most out of their workouts, deciding what and when to eat can be difficult. As anyone who has scarfed down a big meal right before hitting the gym knows, timing matters. Most people need roughly 0.8 g of protein per kilogram of body weight per day, which translates to about 55 g of protein for someone who weighs 150 lbs. Even if you’re looking to build muscle, research suggests that consuming 20-40 g of protein at a time (roughly the…